Asparaginase erythrocyte encapsulated - ERYtech Pharma

Drug Profile

Asparaginase erythrocyte encapsulated - ERYtech Pharma

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase-ERYtech-Pharma; GRASPA; L-asparaginase loaded erythrocytes-ERYtech-Pharma

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ERYtech Pharma
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Acute myeloid leukaemia
  • Preclinical Breast cancer; Non-Hodgkin's lymphoma; Solid tumours
  • Preregistration Submission Withdrawal Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 17 Sep 2018 ERYtech Pharma plans a phase II/III trial for Breast cancer (Combination therapy, Metastatic disease, Locally recurrent) in December 2018 (NCT03674242)
  • 10 Sep 2018 ERYtech Pharma plans the TRYbeCA-1 phase III trial for Pancreatic cancer (Second line treatment) in the Europe in the third quarter of 2018
  • 10 Sep 2018 Erythrocyte-encapsulated asparaginase is still in preclinical development for Solid tumours in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top